List of Excipients in Branded Drug NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

Generic Drugs Containing NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	norethindrone acetate and ethinyl estradiol	0378-7274	.ALPHA.-TOCOPHEROL, DL-
Mylan Pharmaceuticals Inc	norethindrone acetate and ethinyl estradiol	0378-7274	ANHYDROUS LACTOSE
Mylan Pharmaceuticals Inc	norethindrone acetate and ethinyl estradiol	0378-7274	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	norethindrone acetate and ethinyl estradiol	0378-7274	FD&C BLUE NO. 1
Mylan Pharmaceuticals Inc	norethindrone acetate and ethinyl estradiol	0378-7274	LACTOSE MONOHYDRATE
Mylan Pharmaceuticals Inc	norethindrone acetate and ethinyl estradiol	0378-7274	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL?

# Of NDCs	Excipient
2	.ALPHA.-TOCOPHEROL
2	.ALPHA.-TOCOPHEROL, DL-
2	ACACIA
2	ANHYDROUS LACTOSE
1	CALCIUM STEARATE
1	CELLULOSE, MICROCRYSTALLINE

Norethindrone Acetate and Ethinyl Estradiol Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Norethindrone acetate and ethinyl estradiol is a mature combined oral contraceptive market with low API barriers and substantial formulation competition. Commercial opportunity is concentrated in differentiated tablets, chewable delivery, 24/4 regimens, iron-containing placebo tablets, packaging, supply reliability, and products designed for specific excipient tolerability requirements. The core drug combination is generally a generic opportunity rather than a biologic or biosimilar opportunity.

What products contain norethindrone acetate and ethinyl estradiol?

Norethindrone acetate and ethinyl estradiol products are oral contraceptives marketed in multiple hormone strengths and dosing schedules.

Product type	Norethindrone acetate	Ethinyl estradiol	Typical regimen	Commercial relevance
Low-dose monophasic	1 mg	20 mcg	21 active tablets, sometimes 7 placebo tablets	Large generic segment; price competition
Higher-dose monophasic	1.5 mg	30 mcg	21/7 or comparable cycle	Established generic segment
Extended active regimen	1 mg	20 mcg	24 active tablets plus 4 inactive tablets	Differentiated regimen; historical Loestrin 24 Fe positioning
Iron-containing pack	1 mg or 1.5 mg	20 or 30 mcg	Active tablets plus ferrous fumarate tablets	Packaging and adherence differentiation
Chewable tablet	Commonly 1 mg	Commonly 20 mcg	Active and placebo tablets	Excipient and delivery-system opportunity

Representative brand and generic families have included Loestrin, Microgestin, Junel, Blisovi, Hailey and related products. Exact marketed strengths and availability vary by manufacturer and time.

The FDA-approved products are prescription combination hormonal contraceptives. FDA product labeling identifies the active ingredients, dosage regimen, contraindications, warnings and inactive ingredients for each product-specific formulation (U.S. Food and Drug Administration [FDA], 2024a; DailyMed, 2024a).

What excipients are used in norethindrone acetate and ethinyl estradiol tablets?

Common excipients include lactose, starch, povidone, crospovidone, croscarmellose sodium, magnesium stearate, talc, hypromellose, polyethylene glycol, titanium dioxide and colorants. The precise composition varies by manufacturer and dosage strength.

Iron-containing packs generally use ferrous fumarate in the nonhormonal tablets. In Junel Fe-type products, the inactive tablets contain ferrous fumarate, commonly at 75 mg per tablet, equivalent to approximately 25 mg elemental iron. The iron tablets are included for regimen continuity rather than as the contraceptive active ingredient (DailyMed, 2024b).

Excipient functions

Excipient class	Primary function	Key development issue
Lactose or mannitol	Diluent; improves tablet mass and processability	Lactose intolerance positioning and supplier qualification
Microcrystalline cellulose	Diluent and dry-binder	Compactability and tablet robustness
Povidone	Binder	Granulation viscosity and residual moisture
Crospovidone or croscarmellose sodium	Superdisintegrant	Rapid disintegration without excessive friability
Magnesium stearate	Lubricant	Over-lubrication can slow dissolution
Colloidal silicon dioxide	Glidant	Flow improvement at low tablet weight
Hypromellose and PEG	Film-coating system	Moisture protection, appearance and swallowability
Titanium dioxide and iron oxides	Opacifier or colorant	Regulatory and market-specific color requirements
Ferrous fumarate	Inactive-tablet ingredient in Fe packs	Taste, staining, oxidation and content uniformity

The active hormone dose is small, particularly for ethinyl estradiol. Content uniformity, blend segregation and assay sensitivity are therefore more important than tablet mass alone.

What excipient strategy best supports generic development?

The highest-probability strategy is a conventional immediate-release, film-coated tablet using well-characterized compendial excipients. The objective is to achieve bioequivalence, robust dissolution and manufacturing reproducibility without adding formulation complexity that could increase regulatory risk.

Strategy 1: Conventional lactose-based tablet

A lactose-based formulation offers low cost and broad manufacturing familiarity. It is suitable where the target label permits lactose and where the product does not need a lactose-free commercial claim.

The principal risks are blend uniformity for low-dose ethinyl estradiol, moisture sensitivity, and variability in granulation or compression. Direct compression may be attractive for cost and simplicity, but wet granulation can provide better content uniformity and flow where the formulation has poor segregation behavior.

Strategy 2: Lactose-free formulation

A lactose-free tablet can support differentiated labeling for patients who avoid lactose or prefer products without animal-derived or dairy-associated excipients. Mannitol, microcrystalline cellulose, dibasic calcium phosphate or starch-based systems may replace lactose.

The commercial value is limited if the product carries no clear pharmacy or patient-access advantage. The formulation must also avoid creating a larger tablet, slower dissolution profile or higher manufacturing cost.

Strategy 3: Low-moisture, high-uniformity formulation

A low-moisture formulation can reduce degradation risk and improve shelf-life robustness. This may involve direct compression, low-moisture excipient grades, controlled coating conditions and high-barrier packaging.

Potential packaging choices include:

• Alu-Alu blister packs for high moisture and oxygen protection.
• PVC/PVdC or Aclar-based blisters for lower-cost protection.
• High-density polyethylene bottles with desiccant where unit-dose packaging is not required.
• Calendarized blister packs designed to reduce missed doses.

Packaging is often more commercially defensible than a minor excipient substitution because it directly affects adherence, stability and pharmacy handling.

Strategy 4: Chewable or orally disintegrating product

Chewable norethindrone acetate and ethinyl estradiol tablets require a different excipient system. Mannitol, sorbitol, xylitol, microcrystalline cellulose, crospovidone, flavors and sweeteners may be used to achieve acceptable mouthfeel and rapid dispersion.

The main technical barriers are:

• Hormone taste masking.
• Uniform distribution of very low API quantities.
• Tablet strength sufficient for packaging and transport.
• Low friability after chewing.
• Stability of flavor, sweetener and hormone components.
• Dissolution and bioequivalence against the reference product.

A chewable product may have greater commercial differentiation than a standard generic, but the 505(b)(2) or ANDA pathway depends on the reference product, labeling differences and formulation design. A new delivery system can require more clinical and regulatory work than a conventional ANDA.

What formulation patents protect norethindrone acetate and ethinyl estradiol?

The basic active ingredients are old small molecules. The principal commercial patent risk historically centered on product-specific regimens, formulations and branded products rather than composition-of-matter protection for the hormones.

Historical Loestrin 24 Fe litigation involved Warner Chilcott and patents associated with the extended-cycle product. Public patent records and litigation filings identified U.S. Patent No. 6,667,050 among the patents asserted in disputes involving generic versions of Loestrin 24 Fe. The relevant claims concerned product-specific formulation or regimen features rather than a new chemical entity for norethindrone acetate or ethinyl estradiol (U.S. Patent No. 6,667,050; FDA, 2024b).

How strong is the current patent estate?

The estate for a conventional norethindrone acetate and ethinyl estradiol tablet is generally weak relative to newer pharmaceutical products because:

1. The active ingredients have long commercial histories.
2. Multiple generic manufacturers have marketed equivalent strengths.
3. The principal formulation concepts are technically conventional.
4. Commercial value is concentrated in manufacturing scale, distribution and brand recognition.
5. Historical branded-product patents have reached or approached their statutory terms.

A new entrant should still review the current FDA Orange Book, patent listings, litigation records and product-specific labeling before launch. Orange Book status can change as products are discontinued, patents expire, delistings occur or new reference-listed products are added.

What is the FDA regulatory status of these products?

Norethindrone acetate and ethinyl estradiol tablets are regulated as prescription combination oral contraceptives. Generic applicants generally pursue an abbreviated new drug application when the proposed product references an FDA-approved product and can demonstrate pharmaceutical equivalence, bioequivalence and conformity with applicable labeling requirements.

The principal FDA requirements include:

• Same active ingredients as the reference product.
• Matching strength and dosage form.
• Pharmaceutical equivalence.
• Bioequivalence.
• Adequate stability data.
• Demonstration of manufacturing control.
• Compliance with current good manufacturing practice.
• Appropriate labeling and package configuration.

Inactive ingredients may differ in an ANDA if the differences are permissible and do not affect safety, efficacy, bioequivalence or labeling. A chewable product, new dosage form or materially different administration method may create a more complex regulatory pathway.

The FDA Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, remains the primary source for reference-listed products, therapeutic-equivalence codes and listed patent information (FDA, 2024b).

When does norethindrone acetate and ethinyl estradiol lose exclusivity?

The core combination lost meaningful new chemical entity exclusivity decades ago. Current market access is therefore driven by patent status, product-specific regulatory exclusivity, manufacturing approval and commercial execution.

Exclusivity category	Relevance to this combination
New chemical entity exclusivity	No longer relevant for these mature active ingredients
Five-year NCE exclusivity	Not applicable to the established combination
Three-year clinical-investigation exclusivity	Could apply only to a qualifying new approval or change, not automatically to an ordinary generic
Pediatric exclusivity	Product-specific and not a standard feature of the mature market
Patent exclusivity	Historically relevant to branded regimens and formulations
Generic competition	Established across multiple strengths and manufacturers

The practical launch question is not when the hormones lose exclusivity. It is whether a specific reference product has listed patents, regulatory exclusivity or litigation exposure that could delay approval or marketing.

How do Paragraph IV challenges affect generic entry?

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic. For a norethindrone acetate and ethinyl estradiol product, the relevance of Paragraph IV litigation depends on the exact reference product, dosage schedule, formulation and Orange Book listing.

A generic applicant may face:

• A 30-month stay after timely patent litigation by the brand sponsor.
• Settlement terms controlling the earliest launch date.
• Authorized-generic competition.
• Product-specific injunction risk.
• Differences between the 21-day and 24-day regimen patents.

Historical litigation around Loestrin 24 Fe demonstrates that an old contraceptive combination can still generate patent disputes when the commercial product has a differentiated regimen or branded formulation. The risk is substantially lower for an ordinary tablet referencing an unprotected, widely genericized product.

What manufacturing and intellectual-property barriers affect commercial entry?

The primary manufacturing barrier is low-dose uniformity. Ethinyl estradiol is present at microgram strength, making API distribution, sampling and analytical validation critical. Norethindrone acetate is present at a higher but still modest dose.

Important process controls include:

• Controlled API particle-size distribution.
• Geometric dilution or engineered premix for ethinyl estradiol.
• Blend segregation testing.
• In-process weight and hardness controls.
• Assay and content-uniformity testing.
• Dissolution testing across relevant media.
• Protection from humidity, light and oxidation.
• Supplier qualification for hormones, colors and coating materials.

Intellectual-property protection can be created around a specific chewable matrix, extended-release system, taste-masking architecture, packaging configuration, low-dose manufacturing process or stability improvement. Patent value depends on claim breadth, freedom-to-operate and the ability to distinguish the product from existing generic formulations.

A narrow patent covering only a common excipient substitution is unlikely to create durable commercial protection.

Which companies are challenging or competing in the market?

Competition has historically included large generic manufacturers, specialty women’s-health companies and branded product owners. Relevant commercial participants have included Warner Chilcott and its successor organizations for branded Loestrin products, along with generic manufacturers such as Mylan, Teva, Actavis/Watson, Lupin and other FDA-approved applicants.

The competitive market is fragmented by:

• Hormone strength.
• 21/7 versus 24/4 regimen.
• Iron-containing versus non-iron packs.
• Chewable versus swallowable tablets.
• Brand, authorized generic and ordinary generic status.
• Pharmacy-channel contracting.
• Government and managed-care formulary placement.

Company participation should be confirmed against current FDA product listings and National Drug Code data because marketed status changes frequently.

What commercial opportunities exist for excipient innovation?

Adherence-focused packaging

Calendar packs, weekday labeling, tactile differentiation and high-contrast packaging can reduce missed doses. These improvements are more likely to produce commercial value when paired with pharmacy distribution, telehealth fulfillment or direct-to-patient services.

Chewable and taste-masked products

Chewable products can address swallowing difficulty and may support differentiated branding. The commercial opportunity is strongest where the formulation provides a clear patient-use advantage without requiring a difficult clinical program.

Lactose-free and simplified excipient profiles

A lactose-free, low-colorant or low-allergen formulation can support targeted pharmacy and patient positioning. Claims must be supported by the complete formulation, manufacturing process and applicable labeling rules.

Iron-containing regimens

Ferrous fumarate placebo tablets preserve daily dosing behavior and can differentiate the package from a 21-day active-tablet product. The value is primarily regimen continuity and product positioning, not contraceptive efficacy.

Stability and supply-chain improvements

A formulation with superior humidity stability, longer shelf-life or more flexible storage conditions can reduce product loss and support international distribution. This opportunity is particularly relevant for low-cost markets where cold-chain infrastructure is limited, although these products do not generally require refrigerated storage.

How does this market compare with newer contraceptive products?

Norethindrone acetate and ethinyl estradiol has lower patent barriers and lower expected pricing than newer long-acting contraceptives, transdermal systems, vaginal rings and progestin-only products. It also has a larger installed base of prescribers and pharmacists familiar with the dosage form.

Attribute	Norethindrone acetate/ethinyl estradiol	Newer contraceptive delivery systems
Core patent strength	Low	Often higher
Manufacturing complexity	Moderate	Moderate to high
Generic competition	Established	Variable
Differentiation potential	Excipient, regimen, packaging, chewable format	Device, delivery system, duration
Regulatory pathway	Often ANDA for conventional tablets	May require NDA or 505(b)(2)
Price pressure	High	Usually lower initially
Adherence challenge	Daily dosing	Often reduced with long-acting systems

The combination is more attractive as a high-volume, low-margin product or as a platform for patient-use differentiation than as a protected premium product.

What licensing deals and partnering structures are available?

Licensing opportunities are most plausible in four areas:

1. Regional commercialization rights for branded or differentiated products.
2. Technology licensing for chewable or taste-masked tablets.
3. Contract manufacturing and supply agreements.
4. Authorized-generic or private-label arrangements.

A conventional immediate-release generic usually does not require a foundational license to the active ingredients. The relevant negotiation points are product rights, manufacturing capacity, regulatory dossier ownership, territory, minimum purchase commitments, pharmacovigilance obligations and termination rights.

For an innovator formulation, the commercial value of a license depends on whether the patent claims cover a clinically meaningful product attribute and whether the formulation can obtain a differentiated label or market position.

What revenue exposure and launch scenarios should investors assess?

Revenue exposure is concentrated in volume rather than exclusivity. A standard generic launch may produce rapid unit uptake but face multiple competitors and declining price. A differentiated product can support better pricing but carries higher development, regulatory and promotional costs.

Scenario 1: Standard ANDA tablet

This is the lowest-risk path. Expected advantages include a familiar formulation, established analytical methods and a broad pharmacy market. Expected disadvantages include heavy price competition and limited defensibility.

Scenario 2: Iron-containing 24/4 product

This offers regimen and packaging differentiation. The key risks are reference-product selection, patent review and competition from existing generic Fe products.

Scenario 3: Chewable or taste-masked product

This offers stronger product differentiation and may support a specialty or branded-generic strategy. Development risk is higher because palatability, dose uniformity, dissolution and bioequivalence must be controlled.

Scenario 4: International low-cost product

A simplified formulation with robust stability and low-cost packaging may be suited to emerging markets. Geographic expansion requires country-specific registration, local labeling, pharmacovigilance and procurement strategy.

Key Takeaways

• Norethindrone acetate and ethinyl estradiol is a mature, highly genericized oral contraceptive combination.
• Core API patent protection is no longer the commercial driver.
• The most relevant formulation opportunities involve chewable delivery, taste masking, lactose-free composition, iron-containing placebo tablets and adherence-focused packaging.
• Low-dose ethinyl estradiol creates meaningful content-uniformity and analytical-control requirements.
• Historical Loestrin 24 Fe patent litigation shows that regimen and formulation patents can delay specific generic launches.
• A conventional tablet is primarily a scale and cost opportunity.
• A differentiated formulation can support stronger pricing but may require a more complex FDA pathway.
• Biosimilar risk does not apply because the product contains small-molecule active ingredients.
• Current Orange Book listings, patent status and market availability must be assessed at the reference-product level.

FAQs

Is norethindrone acetate and ethinyl estradiol eligible for an ANDA?

Yes. A conventional immediate-release generic tablet can generally use the ANDA pathway when it references an FDA-approved product and meets pharmaceutical-equivalence, bioequivalence, quality and labeling requirements.

Can a new excipient create patent protection for this contraceptive?

Yes, but protection depends on the specific formulation and claim scope. A patent covering a chewable matrix, taste-masking system, stability improvement or manufacturing process is more defensible than a patent covering a routine excipient substitution.

Does ferrous fumarate improve contraceptive efficacy?

No. Ferrous fumarate is used in the nonhormonal tablets of certain Fe packs to maintain daily dosing continuity. The contraceptive activity comes from norethindrone acetate and ethinyl estradiol.

Is a chewable version automatically a 505(b)(2) product?

No. The appropriate pathway depends on the reference product, dosage form, labeling differences and formulation. Some products may qualify for an ANDA, while a materially different delivery system may require a 505(b)(2) application.

Are biosimilars relevant to norethindrone acetate and ethinyl estradiol?

No. Biosimilars apply to biological products. Norethindrone acetate and ethinyl estradiol are small-molecule active ingredients, so competition occurs through generic-drug pathways.

References

1. DailyMed. (2024a). Norethindrone acetate and ethinyl estradiol tablets: Product labeling and inactive ingredients. National Library of Medicine.

2. DailyMed. (2024b). Norethindrone acetate and ethinyl estradiol tablets with ferrous fumarate: Product labeling. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024a). Approved drug product labeling for norethindrone acetate and ethinyl estradiol oral contraceptives. FDA.

4. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.

5. U.S. Patent No. 6,667,050. (2003). Pharmaceutical compositions comprising norethindrone acetate and ethinyl estradiol. United States Patent and Trademark Office.